NCT03620370 is a NA clinical trial of Normobaric oxygen therapy in Stroke, Acute, sponsored by Capital Medical University.

Who is sponsoring NCT03620370?

NCT03620370 is sponsored by Capital Medical University.

What drugs are being tested in NCT03620370?

Interventions in NCT03620370: Normobaric oxygen therapy.

What condition does NCT03620370 study?

NCT03620370 studies Stroke, Acute.

Is NCT03620370 still recruiting?

NCT03620370 is currently completed. Last updated 19 July 2023.

Last reviewed 2023-07-19 · How we verify

NCT03620370

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke

Completed NA Last updated 19 July 2023

What this trial tests

NA trial testing Normobaric oxygen therapy in Stroke, Acute in 86 participants. Completed in 19 October 2019.

Timeline

12 August 2018

Primary endpoint
21 July 2019

19 October 2019

Quick facts

Lead sponsor	Capital Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	86
Start date	12 August 2018
Primary completion	21 July 2019
Estimated completion	19 October 2019
Sites	1 location across China

Drugs / interventions tested

Normobaric oxygen therapy — full drug profile →

Conditions studied

Stroke, Acute — all drugs for Stroke, Acute →

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

NBO is a nonpharmacological measure of neuroprotection. The purpose of our study is to evaluate the safety and efficiency of NBO（Normobaric hyperoxia) in the acute ischemic stroke patients who received endovascular treatment. Looking for more clinical evidence for the ischemic stroke patients who will be treated with NBO in the future.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Normobaric Hyperoxia Combined With Endovascular Treatment for Patients With Acute Ischemic Stroke: A Randomized Controlled Clinical Trial.
Li W, Qi Z, Ma Q, Ding J, et al · · 2022 · cited 39× · PMID 35715198 · DOI 10.1212/wnl.0000000000200775
Ischemic stroke and intervention strategies based on the timeline of stroke progression: Review and prospects.
Xu A, Zhang H, Zhang Y, Wu J, et al · · 2025 · cited 5× · PMID 41049732 · DOI 10.1016/j.apsb.2025.07.026
Enhancing Blood-Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia.
Li W, Hu W, Yuan S, Chen J, et al · · 2024 · cited 5× · PMID 39424403 · DOI 10.1161/jaha.124.036474
Normobaric Hyperoxia Combined with Endovascular Treatment in Patients with Acute Ischemic Stroke (OPENS-2) Trial: Protocol for a Prospective, Multicenter, Randomized Controlled Study.
Li W, Wei M, Liu L, Lan J, et al · · 2024 · cited 2× · PMID 39250887 · DOI 10.1159/000530004
Unmasking the Hidden Burden: Inflammation and Cardiovascular Disease <i>JAHA</i> Spotlight on the Role of the Immune System in Cardiovascular Health and Disease.
Bartoli-Leonard F, Clark DE, Singhal NS, Nguyen PK. · · 2026 · cited 1× · PMID 41294082 · DOI 10.1161/jaha.125.047298
Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.
Niu H, Ding J, Chen Z, Yuan S, et al · · 2026 · cited 1× · PMID 41065265 · DOI 10.1161/jaha.125.041825
Multimodal Neuroprotection in Ischemic Stroke: Emerging Non-Pharmacological Interventions from Bench to Bedside.
Cui J, Yang J, Liu L, Liu X, et al · · 2025 · PMID 41154205 · DOI 10.3390/brainsci15101111
Oxygenation targets for endovascular therapy in acute ischemic stroke patients (Oxy-TARGET): protocol for a single-centre, open-label randomised controlled trial.
Hu Z, Zhang K, Wu Y, Wang X, et al · · 2025 · PMID 39755573 · DOI 10.1136/bmjopen-2024-086234

Verify or expand the search:

Other trials of Normobaric oxygen therapy

Trials testing the same drug.

NCT06946004 — Normobaric Oxygen Therapy in Colorectal Cancer Patients · NA · not yet recruiting
NCT05128422 — Normobaric Hyperoxia Combined With Endovascular Treatment for Acute Ischemic Stroke · NA · completed

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

NCT06825897 — Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiograp · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07253870 — Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients · NA · recruiting
NCT06941753 — Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge · NA · recruiting
NCT06123650 — Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia. · NA · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03620370 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 19 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03620370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing